ZYLORION
LIVE

Serial Number

97102047

Owner

PsiloTec Health Solutions Inc.

Attorney

Charles G. Zug

Filing Date

Nov 1, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ZYLORION Trademark

Serial Number: 97102047 • Registration: 8320275

ZYLORION is a trademark filed by PsiloTec Health Solutions Inc. on November 1, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 29 (Meats & Processed Foods), Class 31 (Natural Agricultural Products), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

PsiloTec Health Solutions Inc. (2 trademarks)

Suite 3500
Calgary, Alberta T2P4J8 , CA

Entity Type: 03

ZYLORION HEALTH INC.

202 6TH AVENUE SW, SUITE 660
CALGARY T2P 2R9 , CA

Entity Type: 99

Trademark Details

Filing Date

November 1, 2021

Registration Date

June 30, 2026

Published for Opposition

May 12, 2026

Goods & Services

Downloadable computer application software for mobile phones for clinical interactions, scheduling appointments, submitting feedback, measuring feedback from biometrics, such as pulse and heart rate, and storing forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; downloadable computer software for clinical interactions, scheduling appointments, submitting feedback, measuring feedback from biometrics, such as pulse and heart rate, and storing forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes

Dried edible mushrooms

Medical and scientific research and product development in the field of psychedelics; medical and scientific research in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; laboratory scientific and medical research in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; providing temporary use of non-downloadable computer software for clinical interactions, scheduling appointments, submitting feedback, measuring feedback from biometrics, such as pulse and heart rate, and storing forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; compiling medical and scientific research data in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes

Psychotherapy services; mental health therapy services for the treatment of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; provision of information to others in the field of mental health; clinical mental health counselling services; compiling medical health information data in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes

Psychedelic medicines for the treatment of psychiatric diseases, namely, mood disorders, depression, mood and emotional instability disorders; psychedelic medicines for the treatment of addiction disorders, namely, alcohol abuse, drug abuse, eating disorders, gambling addiction and sex addiction; psychedelic medicines for the treatment of anxiety disorders, namely, social anxiety, generalized anxiety and panic attack disorder; psychedelic medicines for the treatment of psychological trauma, namely, post-traumatic stress disorder, occupational stress injury, bullying, emotional trauma, physical trauma, work trauma, family violence and grief; psychedelic medicines for the treatment of physical trauma, namely, post-burn injury, post-spinal-cord injury, adult post-amputation, post-brain injury and post-stroke; psychedelic medicines for the treatment of chronic pain, namely, migraines, chronic back pain and chronic arthritis; psychedelic medicines for the treatment of cognitive diseases, namely, cognitive deterioration, early dementia and age-associated memory impairment; psychedelic medicines for the treatment of neuropsychiatric disorders, namely, adult fetal alcohol spectrum disorder, adult attention deficit disorder, adult autism, post-stroke symptoms, multiple sclerosis and Parkinson's disease; psychedelic medicines for the treatment of sleep related disorders, namely, chronic fatigue syndrome, fatigue and insomnia; psychedelic medicines for the treatment of mental health problems experienced by indigenous and other marginalized communities; psychedelic medicines for the treatment of covid-19 symptoms and syndromes

Fresh edible mushrooms

Provision of training in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; provision of education services, namely, providing courses of instruction, classes, seminars, workshops, and conferences in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; provision of training in the field of psychedelic medicines; provision of education services, namely, providing courses of instruction, classes, seminars, workshops, and conferences and training in the field of psychedelic medicines

Data processing services of medical data relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; compiling medical data for business purposes relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 8, 2026 ASGN
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 30, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 30, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 12, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 12, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 6, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 14, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 13, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 13, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 13, 2026 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 12, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 12, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 12, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 17, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 16, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 16, 2025 GNSL
SUSPENSION LETTER WRITTEN
Apr 16, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 16, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 15, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 15, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 15, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 15, 2025 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 17, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 17, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jul 17, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 16, 2024 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 16, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 17, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 17, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 17, 2024 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 19, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 19, 2023 GNSL
SUSPENSION LETTER WRITTEN
Oct 19, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 19, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 19, 2023 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 19, 2023 CHAN
ASSIGNED TO LIE
Oct 19, 2023 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 22, 2023 ERSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 23, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 23, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 23, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 23, 2023 REAP
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 22, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 22, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 22, 2023 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 25, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 25, 2022 GNSL
SUSPENSION LETTER WRITTEN
Aug 25, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 20, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 19, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 19, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 12, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 12, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 12, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 10, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 11, 2021 NWOS
NEW APPLICATION ENTERED
Nov 4, 2021 NWAP